Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous CD19-CD20-NKG2D-nsBicephali CAR-T cells
- Development stage
- Unknown
- Lead developer
- Beijing Gaobo Boren Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous CD19-CD20-NKG2D-nsBicephali CAR-T cells is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy developed by Beijing Boren Hospital. It is designed for the treatment of relapsed or refractory primary and secondary central nervous system lymphoma (CNSL). The therapy involves engineering a patient's own T cells to express a multi-specific CAR that simultaneously targets CD19, CD20, and ligands of the NKG2D receptor (such as MICA/B and ULBPs). This trivalent targeting strategy is intended to overcome tumor antigen heterogeneity and reduce the risk of immune escape associated with the loss or downregulation of a single target. The 'nsBicephali' designation refers to the specific structural architecture of the CAR construct. These engineered cells are designed to migrate into the cerebrospinal fluid and brain parenchyma to directly eliminate malignant B cells within the central nervous system.
- Other names
- Autologous CD19-CD20-NKG2D-nsBicephali CAR-T Cell Injection
02
Targets
CD19 (B lymphocyte antigen CD19)CD20 (B-lymphocyte antigen CD20)MICB (Major histocompatibility complex class i-related protein B)
Beyond the preview
Go deeper on autologous CD19-CD20-NKG2D-nsBicephali CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous CD19-CD20-NKG2D-nsBicephali CAR-T cells.